Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: Experience in two medical centers

Hsueh Erh Chiou, Ching Lung Liu, Mary Jeanne Buttrey, Han Pin Kuo, Hui Wen Liu, Hsu Tah Kuo, Yen Ta Lu

研究成果: 雜誌貢獻文章同行評審

46 引文 斯高帕斯(Scopus)

摘要

Study objectives: To assess the effect of ribavirin-induced anemia on the outcome of severe acute respiratory syndrome (SARS). Design: A retrospective observational study. Setting: Two medical centers in Taiwan. Patients: Forty-four patients with SARS who received ribavirin and 7 patients with SARS who did not receive ribavirin. Measurements and results: The mean peak C-reactive protein and lactate dehydrogenase levels were higher in SARS patients who were receiving ribavirin therapy than in SARS patients who were not receiving ribavirin therapy. The mortality was also higher, but the difference was not statistically significant. On multivariate analysis, hemoglobin level was an independent prognostic correlate of hypoxemia or mortality (odds ratio, 2.0; 95% confidence interval, 1.1 to 3.8; p = 0.03). The hemoglobin began decreasing in two thirds of SARS patients (32 of 44 patients; 73%) who were receiving ribavirin 3 days after therapy with the antiviral drug was started. Patients with a drop in hemoglobin level of > 2 g/dL had a significantly higher mortality rate than the other patients. Hypoxemia developed in one third of SARS patients (17 of 44 patients; 39%) who were receiving ribavirin, all of whom were anemic. Of the 17 hypoxemic patients, 11 (65%) had a drop in hemoglobin of > 2 g/dL, and 4 patients (24%) required a blood transfusion. The mean slope of the hemoglobin decrease was significantly steeper (p = 0.001) in hypoxemic patients with SARS who were receiving ribavirin than in the nonhypoxemic patients with SARS who were receiving ribavirin. Only one of seven SARS patients (14%) who was not receiving ribavirin became anemic, but this individual was not hypoxemic. Eventually, 5 of 17 hypoxemic and anemic SARS patients (29%) who were receiving ribavirin died. The combination of hypoxia with anemia was thus significantly associated with a higher mortality (p < 0.001). Conclusions: Hypoxia combined with anemia increased the risk for death in SARS patients. Unless ribavirin can be shown to be effective against SARS-coronavirus, the risk of anemia posed by this drug argues against its use in SARS patients.
原文英語
頁(從 - 到)263-272
頁數10
期刊Chest
128
發行號1
DOIs
出版狀態已發佈 - 一月 1 2005
對外發佈

ASJC Scopus subject areas

  • 肺和呼吸系統醫學
  • 重症監護和重症監護醫學
  • 心臟病學與心血管醫學

指紋

深入研究「Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: Experience in two medical centers」主題。共同形成了獨特的指紋。

引用此